Phio Pharmaceuticals Corp (PHIO): Kapitalizatsiyaning daromadga nisbati

phiopharma.com (PHIO) brendining ramzi va logotipi

Phio Pharmaceuticals (PHIO) uzoq muddatli opsionlar orqali olimlardan iborat maxsus jamoani saqlab qolmoqda, bu esa onkologik dori vositalarini ishlab chiqishni barqarorlashtiradi. Kompetent menejment INTASYL platformasining intellektual mulkini samarali himoya qilmoqda. GURU.Markets platformasida P/S bozor koeffitsiyentini tahlil qilib, biz belgisi joriy biznesni baholash metriki xizmat qilishini ta'kidlaymiz. Tashuvchisiz genlarni jimjitish bo'yicha fundamental patentlar ushbu sektordagi yangi ishtirokchilar uchun kirishning sezilarli to'siqlarini yaratadi.

P/S multiplikatori: Phio Pharmaceuticals Corp (PHIO) 04.07.2022 - 13.11.2026 uchun

Phio Pharmaceuticals (PHIO) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Narxlar dinamikasi grafigi phiopharma.com|PHIO - Maqsadli narxlar grafigi
- birja kapitallashuvi ma'lumotlari:
Bozor bahosi RXi Pharmaceuticals|PHIO - Korxona qiymati
- xususiy kapitalning balans qiymati ko'rsatkichlari:
Bitta aksiya hisobiga balans qiymati Phio Pharmaceuticals|PHIO - Balans kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati phiopharma.com|PHIO - Kompaniyaning umumiy aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning kapitalga nisbati Phio Pharmaceuticals|PHIO - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati phiopharma.com|PHIO - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati RXi Pharmaceuticals|PHIO - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi Phio Pharmaceuticals|Tezkor likvidlik ko‘rsatkichi phiopharma.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
PHIO - Sof foyda|Prognoz qilingan kelajakdagi foyda Phio Pharmaceuticals|PHIO - Narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati phiopharma.com|PHIO - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati RXi Pharmaceuticals|PHIO - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi 12 oy davomida bitta aksiya uchun foyda Phio Pharmaceuticals|PHIO - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi phiopharma.com|PHIO - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Phio Pharmaceuticals
- emitentning tushumi va sotuvlari tafsilotlari:
PHIO - Kompaniya daromadi|Kompaniyaning kutilayotgan sotish hajmi phiopharma.com|PHIO - P/S multiplikatori|Kapitalizatsiyaning prognoz qilingan daromadga nisbati RXi Pharmaceuticals
Kompaniyaning jamlanma tahliliyoti:Phio Pharmaceuticals Corp
Phio Pharmaceuticals seriyali mahsuloti

Phio Pharmaceuticals (PHIO) kompaniyasining kredit sifatini tahlil qilish generatsiya qilingan pul oqimlari nisbatida bozor qiymatini baholashni talab qiladi. Biznesning barqarorligi INTASYL platformasining noyob, mustaqil yetkazib beruvchi RNK zanjirlariga bo'lgan elastik bo'lmagan talab bilan ta'minlanadi. Ushbu narx-savdo koeffitsiyenti bo'yicha baholash joriy koeffitsiyentning statistik normadan og'ishini standart chetlanishlar orqali o'lchaydi. Ko'rsatkichning ikki sigma chegarasidan tashqariga chiqishi potentsial daromadlar haqida signal beradi, ammo keskin korreksiya xavfi haqida ogohlantiradi.

Raqobatdosh kompaniyalar

TEM (Tempus AI) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Qiagen QGEN|IONS - Kapitalizatsiyaning daromadga nisbati|Repligen Corp. - P/S multiplikatori|RNA - P/S multiplikatori|CRSP: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati genedx.com|RARE (Ultragenyx) - P/S multiplikatori|Sotuvga nisbatan narx Beam Therapeutics Inc BEAM|Kapitalizatsiyaning daromadga nisbati SRPT (Sarepta Therapeutics Inc)|P/S multiplikatori Twist Bioscience Corp (TWST)|10x Genomics, Inc. - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati NTLA (intelliatx.com)|Stoke Therapeutics, Inc. - P/S multiplikatori|Narx/daromad koeffitsiyenti BioLife Solutions Inc BLFS|WVE: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Maze Therapeutics Corp|SION (Sionna Therapeutics Inc) - P/S multiplikatori|P/S multiplikatori primemedicine.com|Narxning daromadga nisbati Taysha Gene Therapies, Inc. (TSHA)|Narxning daromadga nisbati QURE (uniQure NV)|Narxning daromadga nisbati MeiraGTx PLC MGTX|Narx/daromad koeffitsiyenti REGENXBIO Corp (RGNX)|SLDB - Narxning daromadga nisbati|Narxning sotuvga nisbati OCGN|PACB: P/S multiplikatori|Benitec Biopharma Inc - Bozor kapitallashuvining daromadga nisbati|DSGN (Design Pharma) - P/S multiplikatori|Rocket Corp (RCKT) - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati 4D Molecular Therapeutics (FDMT)|LXEO - Sotuvga nisbatan narx|P/S multiplikatori KRRO (Korro Bio)|EDIT: Kapitalizatsiya va daromad nisbati|SLN - Narxning daromadga nisbati|PRQR (ProQR Therapeutics N.V.) - Kapitalizatsiya va daromad nisbati|CDXS: P/S multiplikatori|sangamo.com (SGMO) - P/S multiplikatori|Narxning daromadga nisbati Nautilus Biotechnology, Inc.|Metagenomi Inc. - Narxning sotuvga nisbati|P/S multiplikatori DTIL|GBIO (generationbio.com) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori BOLD (Boundless Bio, Inc.)|Narx/daromad koeffitsiyenti Exicure Inc. (XCUR)|IMNN - Narxning daromadga nisbati|Sotuvga nisbatan narx Mustang Bio, Inc.|RNAZ (transcodetherapeutics.com) - Kapitalizatsiyaning daromadga nisbati|Bionano Genomics - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Applied DNA Sciences|bluebirdbio.com - Narxning sotuvga nisbati|P/S multiplikatori IPA|OMGA (Omega Therapeutics Inc) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori OMIC (Singular Genomics Systems Inc)|P/S multiplikatori Regulus RGLS|SYRS - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati TBIO (telesisbio.com)|TRACON Pharmaceuticals, Inc. (TCON) - Narxning daromadga nisbati|Kapitalizatsiyaning daromadga nisbati Unity Biotechnology Inc.